T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-08-25Clinical Trial Update: Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma [Phase 2]
This Phase 2 trial update describes BuEAM conditioning with busulfan, etoposide, cytarabine, and melphalan before autologous stem cell trans…
-
CLINICAL_TRIALS research · 2014-08-06Clinical Trial Update: Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma
This update describes an ongoing clinical trial evaluating Helical Tomotherapy-based Total Skin irradiation (HITS) for T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2014-06-12Clinical Trial Update: Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma [Phase 2]
Phase 2 study evaluating fostamatinib disodium for T-cell lymphoma has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2013-09-23Clinical Trial Update: Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies [Phase 1]
A Phase 1 study of oral forodesine hydrochloride (BCX-1777) in patients with recurrent or refractory T/NK-cell malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2013-07-26Clinical Trial Update: Aminocamptothecin in Treating Patients With T-cell Lymphoma [Phase 2]
Update on a Phase 2 trial evaluating aminocamptothecin in patients with T-cell lymphoma, noting completed status.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-05-30Clinical Trial Update: Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating dexamethasone followed by denileukin diftitox in persistent or recurrent T-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2013-02-12Clinical Trial Update: Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma [Phase 2]
Phase 2 trial evaluating bendamustine in patients with refractory or relapsed T-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2012-10-24Clinical Trial Update: Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas [Phase 2]
Phase 2 trial update for Anti-Tac(Fv)-PE38 (LMB-2) in cutaneous T-cell lymphomas has been completed with results posted in 2012.
-
CLINICAL_TRIALS trial_result · 2012-08-29Clinical Trial Update: UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas [Phase 2]
Phase 2 trial of UCN-01 (7-Hydroxystaurosporine) for relapsed T-cell lymphomas was terminated, with results posted in 2012.
-
EMA withdrawal · 2012-07-11EMA Refused: Folotyn (pralatrexate) — Allos Therapeutics Ltd
EMA refused approval for Folotyn (pralatrexate) by Allos Therapeutics Ltd for T-cell lymphoma indications.
-
CLINICAL_TRIALS trial_result · 2012-06-12Clinical Trial Update: Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
This is a completed Phase 1/Phase 2 trial evaluating chemotherapy and radiation therapy with bone marrow or peripheral stem cell transplanta…
-
CLINICAL_TRIALS trial_result · 2011-11-07Clinical Trial Update: Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma [Phase 2]
A Phase 2 study evaluating autologous and allogeneic transplantation with Campath-1H (alemtuzumab) for T-cell lymphoma was terminated, with …
-
CLINICAL_TRIALS trial_result · 2011-07-20Clinical Trial Update: Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma [Phase 1]
Phase 1 trial assessing intratumoral Poly-ICLC with low-dose local radiation in low-grade recurrent B-cell and T-cell lymphomas; the study w…
-
CLINICAL_TRIALS trial_result · 2009-03-12Clinical Trial Update: PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) [Phase 2]
Phase 2 clinical trial update on PF-3512676 (CPG 7909) for patients who completed an oncology study using the drug. The document notes that …
-
CLINICAL_TRIALS trial_result · 2008-10-22Clinical Trial Update: Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma [Phase 1]
Phase 1 study evaluating CHOP chemotherapy in combination with Campath (alemtuzumab) for T-cell lymphoma, NK-cell lymphoma, and other non-Ho…